FEMY News and Press, Femasys Inc. From 09/01/21

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform wome...

Completed initial public offering (“IPO”) raising net proceeds of $31.6 million Appointed Anne Morrissey to the Board of Directors, an industry expert with decades of medical device experience Initiated 792-patient, pivotal LOCAL trial after receipt of inve...

Gainers: NeuroMetrix NURO +233%.NeuroBo Pharmaceuticals NRBO +92%.Staffing 360 Solutions (STAF) +38%.LSB Industries (LXU) +36%.Femasys (FEMY) +27%.Ideal Power (IPWR) +26%.Endo International plc ENDP +25%.PainReform (PRFX) +21%.LifeVantage Corporation (LFVN) +16%.Immunome IMNM&#...

Gainers: NeuroMetrix (NURO) +161%.NeuroBo Pharmaceuticals (NRBO) +45%.LSB Industries (LXU) +35%.Staffing 360 Solutions (STAF) +24%.Endo International plc (ENDP) +23%.Pop Culture Group (CPOP) +23%.Immunome (IMNM) +19%.Ideal Power (IPWR) +19%.Femasys (FEMY) +16HCA Healthcare (HCA) +15%.Los...

Gainers: NeuroMetrix (NURO) +161%.NeuroBo Pharmaceuticals (NRBO) +45%.LSB Industries (LXU) +35%.Staffing 360 Solutions (STAF) +24%.Endo International plc (ENDP) +23%.Pop Culture Group (CPOP) +23%.Immunome (IMNM) +19%.Ideal Power (IPWR) +19%.Femasys (FEMY) +16HCA Healthcare (HCA) +15%.Los...

First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers ATLANTA, July 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women's healthcare, today anno...

Femasys Inc. (NASDAQ:FEMY) traded today at a new 52-week low of $6.83. This new low was reached on above average trading volume as 578,000 shares traded hands, while the average 30-day volume is approximately 239,000 shares. Potential upside of 9.2% exists for Femasys Inc., based on a cu...

Femasys has the potential to transform both birth control and infertility, both of which are multibillion-dollar markets. The company has received a $50mil investment from Medtronic and more recently, existing investors bought into the IPO. Commercialization of FemaSeed will be he...

Shares of Femasys Inc. (NASDAQ:FEMY) traded today at $8.34, breaking its 52-week low. Approximately 255,000 shares have changed hands today, as compared to an average 30-day volume of 0,000 shares. In the past 52 weeks, shares of Femasys Inc. have traded between the current low of $8.34 ...

Shares of Femasys Inc. (NASDAQ:FEMY) traded at a new 52-week low today of $9.65. So far today approximately 117,000 shares have been exchanged, as compared to an average 30-day volume of 0,000 shares. Femasys Inc is a biomedical company focused on transforming women's healthcare by devel...